Company intelligence / Profile preview

NVH

Canada

Ownership: Private
Development stage: Commercial

Overview

Novoheart has pioneered a range of bioengineering technologies collectively known as the MyHeart platform, including the first human mini-heart ("novoHeart") capable of pumping and ejecting fluid. The company partners with pharmaceutical firms to develop human heart tissues that model hereditary neurodegenerative diseases, enabling unique drug discovery and screening platforms targeting cardiac complications. They are expanding commercial laboratory capacity in Asia to support additional partnerships.

Therapeutic areas: Cardiovascular
Modalities: Cell therapyBiologic
Industry: Non-Drug Biotech

Partnerships

Partnering with an unnamed pharmaceutical company for development of pathological human heart tissues/organoids used in drug discovery/screening platforms targeting specific inherited neurological/cardiac conditions.

Beyond the preview

Go deeper on NVH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVH.

Explore the full profile